Andrea Botticelli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients	JOURNAL OF PERSONALIZED MEDICINE	2020
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137 + T-cells	EBIOMEDICINE	2020
Network analysis of gut microbiome and metabolome to discover microbiota-linked biomarkers in patients affected by non-small cell lung cancer	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	2020
Primary squamous cell carcinoma of major salivary gland: “Sapienza Head and Neck Unit” clinical recommendations	RARE TUMORS	2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events	EUROPEAN JOURNAL OF CANCER	2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study	ONCOIMMUNOLOGY	2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors. the multicenter FAMI-L1 study	ONCOIMMUNOLOGY	2020
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden	ANNALS OF ONCOLOGY	2020
IgM-rheumatoid factor as a novel biomarker for a reduced survival in anti-PD-1 treated NSCLC patients through the decrease of CD137+T-cells	ANNALS OF ONCOLOGY	2020
Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions	JOURNAL OF IMMUNOLOGY RESEARCH	2020
Neoadjuvant immune-checkpoint blockade in triple-negative breast cancer: current evidence and literature-based meta-analysis of randomized trials	CANCERS	2020
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series	JOURNAL OF PERSONALIZED MEDICINE	2020
Palbociclib plus fulvestrant or everolimus plus exemestane for pretreated advanced breast cancer with lobular histotype in ER+/HERr2− patients: A propensity score-matched analysis of a multicenter retrospective patient series	JOURNAL OF PERSONALIZED MEDICINE	2020
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis	JOURNAL OF TRANSLATIONAL MEDICINE	2020
Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors	IMMUNOTHERAPY	2020
Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients	JOURNAL OF PERSONALIZED MEDICINE	2020
Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options	CANCER MANAGEMENT AND RESEARCH	2020
Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: Are we ready to endorse axillary conservation?	THE BREAST JOURNAL	2019
Impact of tumor site on the prognosis of small bowel adenocarcinoma	TUMORI	2019

Progetti di Ricerca

Window therapy with CDK 4/6 inhibitors in head and neck cancer patients treated with immunotherapy